Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (COVID-19)

AI Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) issued temporary guidance for the Valproate Pregnancy Prevention Programme (PPP) to address challenges posed by the COVID-19 pandemic. Valproate is associated with a 10% risk of congenital malformations and a 30–40% risk of neurodevelopmental disorders in children exposed in utero. To mitigate these risks while maintaining social distancing, the MHRA updated its regulatory framework to allow for remote management of high-risk patients. While new treatments generally require face-to-face initiation, annual reviews for existing patients should proceed via video or telephone to avoid delays in care. Prescribers must use the Annual Risk Acknowledgment Form (ARAF) to document patient understanding, accepting verbal confirmation and electronic signatures where physical meetings are impossible. Home pregnancy testing is also permitted, provided results are verified by a clinician via digital means. Required actions for healthcare providers include prioritizing contraceptive access, ensuring comprehensive documentation in medical records, and reporting all suspected adverse reactions through the Yellow Card scheme. These measures ensure that the safety requirements for valproate use remain robust despite pandemic-related restrictions.